Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial.

Ferrante KL, Wasenda EJ, Jung CE, Adams-Piper ER, Lukacz ES.

Female Pelvic Med Reconstr Surg. 2019 Jun 19. doi: 10.1097/SPV.0000000000000749. [Epub ahead of print]

PMID:
31232721
2.

Teaching Vaginal Hysterectomy via Simulation: Creation and Validation of the Objective Skills Assessment Tool for Simulated Vaginal Hysterectomy on a Task Trainer and Performance Among Different Levels of Trainees.

Malacarne DR, Escobar CM, Lam CJ, Ferrante KL, Szyld D, Lerner VT.

Female Pelvic Med Reconstr Surg. 2019 Jul/Aug;25(4):298-304. doi: 10.1097/SPV.0000000000000558.

PMID:
29443815
3.

Urologic and Gynecologic Sources of Pelvic Pain.

Malacarne DR, Ferrante KL, Brucker BM.

Phys Med Rehabil Clin N Am. 2017 Aug;28(3):571-588. doi: 10.1016/j.pmr.2017.03.008. Epub 2017 May 27. Review.

PMID:
28676365
4.

A randomized trial of vaginal mesh attachment techniques for minimally invasive sacrocolpopexy.

Tan-Kim J, Nager CW, Grimes CL, Luber KM, Lukacz ES, Brown HW, Ferrante KL, Dyer KY, Kirby AC, Menefee SA.

Int Urogynecol J. 2015 May;26(5):649-56. doi: 10.1007/s00192-014-2566-8. Epub 2014 Nov 25.

PMID:
25421934
5.

Repeat post-op voiding trials: an inconvenient correlate with success.

Ferrante KL, Kim HY, Brubaker L, Wai CY, Norton PA, Kraus SR, Shepherd J, Sirls LT, Nager CW; Urinary Incontinence Treatment Network.

Neurourol Urodyn. 2014 Nov;33(8):1225-8. doi: 10.1002/nau.22489. Epub 2013 Aug 27.

6.

Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.

Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M.

Neurology. 2005 Dec 13;65(11):1834-6.

PMID:
16344537
7.

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.

Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ.

J Neurochem. 2003 Jun;85(6):1359-67.

8.

Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF.

J Neurosci. 2002 Mar 1;22(5):1592-9.

9.

Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease.

Andreassen OA, Ferrante RJ, Huang HM, Dedeoglu A, Park L, Ferrante KL, Kwon J, Borchelt DR, Ross CA, Gibson GE, Beal MF.

Ann Neurol. 2001 Jul;50(1):112-7.

PMID:
11456300
10.

Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.

Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF.

Neurobiol Dis. 2001 Jun;8(3):479-91.

PMID:
11447996
11.

Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation.

Andreassen OA, Jenkins BG, Dedeoglu A, Ferrante KL, Bogdanov MB, Kaddurah-Daouk R, Beal MF.

J Neurochem. 2001 Apr;77(2):383-90.

12.

Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice.

Andreassen OA, Dedeoglu A, Friedlich A, Ferrante KL, Hughes D, Szabo C, Beal MF.

Exp Neurol. 2001 Apr;168(2):419-24.

PMID:
11259130

Supplemental Content

Loading ...
Support Center